447 related articles for article (PubMed ID: 29138340)
1. Phase I Study of Chimeric Antigen Receptor-Modified T Cells in Patients with EGFR-Positive Advanced Biliary Tract Cancers.
Guo Y; Feng K; Liu Y; Wu Z; Dai H; Yang Q; Wang Y; Jia H; Han W
Clin Cancer Res; 2018 Mar; 24(6):1277-1286. PubMed ID: 29138340
[No Abstract] [Full Text] [Related]
2. Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers.
Feng K; Liu Y; Guo Y; Qiu J; Wu Z; Dai H; Yang Q; Wang Y; Han W
Protein Cell; 2018 Oct; 9(10):838-847. PubMed ID: 28710747
[TBL] [Abstract][Full Text] [Related]
3. Anti-EGFR chimeric antigen receptor-modified T cells in metastatic pancreatic carcinoma: A phase I clinical trial.
Liu Y; Guo Y; Wu Z; Feng K; Tong C; Wang Y; Dai H; Shi F; Yang Q; Han W
Cytotherapy; 2020 Oct; 22(10):573-580. PubMed ID: 32527643
[TBL] [Abstract][Full Text] [Related]
4. Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers.
Haas AR; Tanyi JL; O'Hara MH; Gladney WL; Lacey SF; Torigian DA; Soulen MC; Tian L; McGarvey M; Nelson AM; Farabaugh CS; Moon E; Levine BL; Melenhorst JJ; Plesa G; June CH; Albelda SM; Beatty GL
Mol Ther; 2019 Nov; 27(11):1919-1929. PubMed ID: 31420241
[TBL] [Abstract][Full Text] [Related]
5. Anti-CD123 chimeric antigen receptor T-cells (CART): an evolving treatment strategy for hematological malignancies, and a potential ace-in-the-hole against antigen-negative relapse.
Cummins KD; Gill S
Leuk Lymphoma; 2018 Jul; 59(7):1539-1553. PubMed ID: 28901790
[TBL] [Abstract][Full Text] [Related]
6. Cocktail treatment with EGFR-specific and CD133-specific chimeric antigen receptor-modified T cells in a patient with advanced cholangiocarcinoma.
Feng KC; Guo YL; Liu Y; Dai HR; Wang Y; Lv HY; Huang JH; Yang QM; Han WD
J Hematol Oncol; 2017 Jan; 10(1):4. PubMed ID: 28057014
[TBL] [Abstract][Full Text] [Related]
7. Pilot Trial of Adoptive Transfer of Chimeric Antigen Receptor-transduced T Cells Targeting EGFRvIII in Patients With Glioblastoma.
Goff SL; Morgan RA; Yang JC; Sherry RM; Robbins PF; Restifo NP; Feldman SA; Lu YC; Lu L; Zheng Z; Xi L; Epstein M; McIntyre LS; Malekzadeh P; Raffeld M; Fine HA; Rosenberg SA
J Immunother; 2019 May; 42(4):126-135. PubMed ID: 30882547
[TBL] [Abstract][Full Text] [Related]
8. Current landscape for chimeric antigen receptor T cells in lymphomas.
Skarbnik AP
Curr Opin Hematol; 2019 Nov; 26(6):421-426. PubMed ID: 31483334
[TBL] [Abstract][Full Text] [Related]
9. Long-term safety and activity of NY-ESO-1 SPEAR T cells after autologous stem cell transplant for myeloma.
Stadtmauer EA; Faitg TH; Lowther DE; Badros AZ; Chagin K; Dengel K; Iyengar M; Melchiori L; Navenot JM; Norry E; Trivedi T; Wang R; Binder GK; Amado R; Rapoport AP
Blood Adv; 2019 Jul; 3(13):2022-2034. PubMed ID: 31289029
[TBL] [Abstract][Full Text] [Related]
10. Dual Targeting of Mesothelin and CD19 with Chimeric Antigen Receptor-Modified T Cells in Patients with Metastatic Pancreatic Cancer.
Ko AH; Jordan AC; Tooker E; Lacey SF; Chang RB; Li Y; Venook AP; Tempero M; Damon L; Fong L; O'Hara MH; Levine BL; Melenhorst JJ; Plesa G; June CH; Beatty GL
Mol Ther; 2020 Nov; 28(11):2367-2378. PubMed ID: 32730744
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of failure of chimeric antigen receptor T-cell therapy.
Li X; Chen W
Curr Opin Hematol; 2019 Nov; 26(6):427-433. PubMed ID: 31577606
[TBL] [Abstract][Full Text] [Related]
12. Neurotoxicity and Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy: Insights Into Mechanisms and Novel Therapies.
Siegler EL; Kenderian SS
Front Immunol; 2020; 11():1973. PubMed ID: 32983132
[TBL] [Abstract][Full Text] [Related]
13. CART Targeting of Solid Tumors: More Pieces to the Puzzle.
Kalos M
Clin Cancer Res; 2018 Mar; 24(6):1246-1247. PubMed ID: 29348296
[TBL] [Abstract][Full Text] [Related]
14. Phase I clinical trial of EGFR-specific CAR-T cells generated by the piggyBac transposon system in advanced relapsed/refractory non-small cell lung cancer patients.
Zhang Y; Zhang Z; Ding Y; Fang Y; Wang P; Chu W; Jin Z; Yang X; Wang J; Lou J; Qian Q
J Cancer Res Clin Oncol; 2021 Dec; 147(12):3725-3734. PubMed ID: 34032893
[TBL] [Abstract][Full Text] [Related]
15. Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells.
Wang Y; Zhang WY; Han QW; Liu Y; Dai HR; Guo YL; Bo J; Fan H; Zhang Y; Zhang YJ; Chen MX; Feng KC; Wang QS; Fu XB; Han WD
Clin Immunol; 2014 Dec; 155(2):160-75. PubMed ID: 25444722
[TBL] [Abstract][Full Text] [Related]
16. Long-Term Outcomes From a Randomized Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells in Relapsed Chronic Lymphocytic Leukemia.
Frey NV; Gill S; Hexner EO; Schuster S; Nasta S; Loren A; Svoboda J; Stadtmauer E; Landsburg DJ; Mato A; Levine BL; Lacey SF; Melenhorst JJ; Veloso E; Gaymon A; Pequignot E; Shan X; Hwang WT; June CH; Porter DL
J Clin Oncol; 2020 Sep; 38(25):2862-2871. PubMed ID: 32298202
[TBL] [Abstract][Full Text] [Related]
17. Chimeric Antigen Receptor-Engineered T Cell Therapy for the Management of Patients with Metastatic Prostate Cancer: A Comprehensive Review.
Yu YD; Kim TJ
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33440664
[TBL] [Abstract][Full Text] [Related]
18. Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors.
Zhang E; Gu J; Xu H
Mol Cancer; 2018 Jan; 17(1):7. PubMed ID: 29329591
[TBL] [Abstract][Full Text] [Related]
19. Advances in off-the-shelf CAR T-cell therapy.
Benjamin R
Clin Adv Hematol Oncol; 2019 Mar; 17(3):155-157. PubMed ID: 30969953
[No Abstract] [Full Text] [Related]
20. CAR T-cell therapy against B-cell maturation antigen in multiple myeloma.
Cohen AD
Clin Adv Hematol Oncol; 2018 Dec; 16(12):804-806. PubMed ID: 30843888
[No Abstract] [Full Text] [Related]
[Next] [New Search]